Blue Flower

TEL AVIV, Israel (EuropaWire) In 1964 Professor Raphael Mechoulam was on a public bus carrying 5 kilos of premium Lebanese hashish in a plastic bag to his laboratory at the Weitzmann Institute in Rehovot. That noticeably fragrant bus ride turned out to be a fateful one, as Mechoulam used his haul to discover the psychoactive component in Cannabis, Tetrahydrocannabinol (THC). It was a discovery that had eluded scientists for decades. Twenty years later, Mechoulam ascertained that THC interacts with the largest receptor system in the human body, the endocannabinoid system (ECS). He then found that the human brain produces its very own cannabis—a chemical that they named anandamide after the Sanskrit word ananda, “bliss.”   Please see remainder of this article on the CBD Project Website.

Below is an excellent hour long history video by Zack Klein of the work and discoveries concerning Dr. Mechoulam and the Endocannabinoid system.   "The Scientist" is a documentary that traces the story of Nobel price nominee Dr Mechoulam from his early days......as a child of the Holocaust in Bulgaria, through his immigration to Israel, and his career as the chief investigator into the chemistry and biology of the world's most misunderstood plant. Dr. Mechoulam ascertained that THC interacts with the largest receptor system in the human body, the endocannabinoid system (ECS).

Ohio Medical Marihuana Legislation Suggestions

FOR IMMEDIATE RELEASE:                                                                                                                       3/31/2016

Press Release Link for PDF copy

 

Ohio Patient Network (OPN) makes the following additional legislation for the task force & Ohio legislators to consider.  Previously OPN issued recommendation on 3-17-2016.  The following are more detailed suggestions, OPN still suggest HB214 from Ohio’s 129th legislative session as a starting point.

 

  • Patient self sufficiency

◦     Patients enabled to grow limited amounts for self-use

▪     Restrictions from being engaged in commerce with home grown marihuana

▪     Enable caregiver assistance with reasonable state control & authorization

▪     Patients to have a bone fide relationship with a recommending medical professional

◦     Enable legal protections for patients, caregiver, suppliers and medical professionals

 

  • Regulated commercial medical supply

◦     Include quality, safety, testing & compliance mechanisms

◦     Tax based upon THC percentage to provide funding for

▪     Commission members and activity

▪     Legal oversight of commercial supply chain

▪     Supporting Medical Research

 

  • State Commission with regulatory oversight

◦     Suggest appointments made by legal, medical & law enforcement & patient advocates’ organizations.

▪     (Patient, Nurse, Medical, Pharmacy, Law Enforcement, Civil Rights, etc, etc)

◦     Have Legislators & Governor appointed commission members

◦     Have no restrictions on commission memberships

▪     (i.e. political office holder, past felon, etc)

 

 

  • Remove marihuana from schedule one in Ohio’ controlled substance/drug schedule
  • Enable Ohio medical research organizations to use Ohio grown marijuana
  • Encourage/Utilize banking similar in manner as the State of Vermont has done.
  • Delay infused edibles products for the next General Assembly to detail regulation & laws
  • Establish a political Blue Ribbon panel to look at the future of marihuana/cannabis laws on a variety of potential topics such as hemp, industrial, farming, medical, and driving.

 

Ohio Patient Network contact is Rob Ryan, a three time cancer survivor.

 Office 513-442-4495                                                                     email This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Jerusalem, Israel: The daily, long-term use of cannabis is associated with improved analgesia and reduced opioid use in patients with treatment-resistant chronic pain conditions, according to clinical trial data reported online ahead of print in The Clinical Journal of Pain.

Investigators with Hebrew University in Israel evaluated the use of cannabis on pain in a cohort of 176 patients, each of whom had been previously unresponsive to all conventional pain medications. Subjects inhaled THC-dominant cannabis daily (up to 20 grams per month) for a period of at least six months.

A majority of participants (66 percent) experienced improvement in their pain symptom scores after cannabis therapy, and most reported "robust" improvements in their quality of life. Subjects' overall consumption of opioid drugs declined 44 percent by the end of the trial, and a significant percentage of participants discontinued opioid therapy altogether over the course of the study.

Authors concluded, "In summary, this long-term prospective cohort suggests that cannabis treatment in a mixed group of patients with treatment-resistant chronic pain may result in improved pain, sleep and quality of life outcomes, as well as reduced opioid use."

The Israeli results are similar to those reported in a 2015 Canadian trial which concluded that chronic pain patients who use herbal cannabis daily for one-year experienced reduced discomfort and increased quality of life compared to controls, and did not possess an increased risk of serious side effects.

Separate data published in 2014 in The Journal of the American Medical Association determined that states with medical marijuana laws experience far fewer opiate-related deaths than do states that prohibit the plant. Investigators from the RAND Corporation reported similar findings in 2015, concluding, "States permitting medical marijuana dispensaries experience a relative decrease in both opioid addictions and opioid overdose deaths compared to states that do not." Clinical data published in 2011 in the journal Clinical Pharmacology & Therapeutics previously reported that the administration of vaporized cannabis "safely augments the analgesic effect of opioids."

A scientific review published earlier this year assessing the clinical use of cannabinoids for pain in over 1,300 subjects concluded, "Overall, the recent literature supports the idea that currently available cannabinoids are modestly effective analgesics that provide a safe, reasonable therapeutic option for managing chronic non-cancer-related pain and possibly cancer-related pain."

Full text of the study, "The effect of medicinal cannabis on pain and quality of life outcomes in chronic pain: A prospective open-label study," appears in The Clinical Journal of Pain.  See the United States Government's  National Center for Biotechnology Information website for the abstract

Legislative suggestions Ohio Medical Marihuana

FOR IMMEDIATE RELEASE:                                                                                                                       3/17/2016

Press Release Link for PDF copy

 

 

Ohio Patient Network (OPN) makes the following suggestions for potential legislation for the task force & Ohio legislators to consider.  Ohio legislators have a rich source of material to draw from in the LSC historical database.  OPN suggest HB214 from Ohio’s 129th legislative session as an acceptable starting point.

·        Patient self sufficiency

◦     Patients are enabled to grow for self-use, with restrictions from being engaged in commerce

▪     Enable caregiver assistance with reasonable state authorizations

◦     Legal protections for patients, caregiver, suppliers and medical professionals

 

·        Regulated commercial medical supply

◦     Includes quality, safety, testing & compliance mechanisms

◦     Taxes to provide funding for

▪     Commission members and activity

▪     Legal oversight of commerce activity

▪     Supporting Medical Research

 

·        State Commission with regulatory oversight

◦     Suggest appointments made by legal, medical & law enforcement & patient advocates’ organizations.

▪     (Patient, Nurse, Medical, Pharmacy, Law Enforcement, Civil Rights, etc, etc)

◦     Have Legislators & Governor appointed commission members

◦     Have no restrictions on commission memberships

▪     (i.e. political office holder, past felon, etc)

 

·        Establish political Blue Ribbon panel on future of cannabis laws

◦     Reports, studies and recommendation to legislators.

 

Ohio Patient Network contact is Rob Ryan, a three time cancer survivor.

 Office 513-442-4495                                                                     email This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Chronic pain patients who use herbal cannabis daily for one-year report reduced discomfort and increased quality of life compared to controls, and do not experience an increased risk of serious side effects, according to clinical data published online ahead of print in the Journal of Pain.

Researchers at McGill University in Montreal assessed the long-term health of 216 medicinal cannabis users with chronic non-cancer pain who consumed a daily standardized dose (12.5 percent THC) of herbal cannabis compared to 215 controls (chronic pain suffers who did not use cannabis). Subjects in study were approved by Health Canada to legally use medicinal cannabis and consumed, on average, 2.5 grams of herb per day, typically via inhalation or vaporization.

Investigators reported that daily cannabis consumers possessed no greater risk than non-users to experience “serious adverse events.” Specifically, researchers identified no significant adverse changes in consumers’ cognitive skills, pulmonary function, or blood work following one-year of daily cannabis consumption. Medical cannabis consumers did report elevated risk of experiencing “non-serious adverse events” (e.g., cough, dizziness, paranoia) compared to controls; however, authors classified these to be “mild to moderate.”

Pain patients who used cannabis reported a reduced sense of pain compared to controls, as well as reduced anxiety, depression, and fatigue.

“Quality-controlled herbal cannabis, when used by cannabis-experienced patients as part of a monitored treatment program over one year, appears to have a reasonable safety profile,” authors concluded.

The study is one of the first to ever assess the long-term safety and efficacy of medicinal cannabis. A prior health review of patients receiving medical cannabis monthly from the US federal government as part of the Compassionate Investigational New Drug program similarly reported that cannabis possesses therapeutic efficacy and an acceptable side-effect profile.

See full text of the study, “Cannabis for the Management of Pain: Assessment of Safety Study,” online.

Chronic pain patients who use herbal cannabis daily for one-year report reduced discomfort and increased quality of life compared to controls, and do not experience an increased risk of serious side effects, according to clinical data published online ahead of print in the Journal of Pain.

Researchers at McGill University in Montreal assessed the long-term health of 216 medicinal cannabis users with chronic non-cancer pain who consumed a daily standardized dose (12.5 percent THC) of herbal cannabis compared to 215 controls (chronic pain suffers who did not use cannabis). Subjects in study were approved by Health Canada to legally use medicinal cannabis and consumed, on average, 2.5 grams of herb per day, typically via inhalation or vaporization.

Investigators reported that daily cannabis consumers possessed no greater risk than non-users to experience “serious adverse events.” Specifically, researchers identified no significant adverse changes in consumers’ cognitive skills, pulmonary function, or blood work following one-year of daily cannabis consumption. Medical cannabis consumers did report elevated risk of experiencing “non-serious adverse events” (e.g., cough, dizziness, paranoia) compared to controls; however, authors classified these to be “mild to moderate.”

Pain patients who used cannabis reported a reduced sense of pain compared to controls, as well as reduced anxiety, depression, and fatigue.

“Quality-controlled herbal cannabis, when used by cannabis-experienced patients as part of a monitored treatment program over one year, appears to have a reasonable safety profile,” authors concluded.

The study is one of the first to ever assess the long-term safety and efficacy of medicinal cannabis. A prior health review of patients receiving medical cannabis monthly from the US federal government as part of the Compassionate Investigational New Drug program similarly reported that cannabis possesses therapeutic efficacy and an acceptable side-effect profile.

- See more at: http://blog.norml.org/2015/09/21/study-daily-cannabis-use-for-chronic-pain-is-safe-effective/#sthash.DqnS90PL.dpuf

Chronic pain patients who use herbal cannabis daily for one-year report reduced discomfort and increased quality of life compared to controls, and do not experience an increased risk of serious side effects, according to clinical data published online ahead of print in the Journal of Pain.

Researchers at McGill University in Montreal assessed the long-term health of 216 medicinal cannabis users with chronic non-cancer pain who consumed a daily standardized dose (12.5 percent THC) of herbal cannabis compared to 215 controls (chronic pain suffers who did not use cannabis). Subjects in study were approved by Health Canada to legally use medicinal cannabis and consumed, on average, 2.5 grams of herb per day, typically via inhalation or vaporization.

Investigators reported that daily cannabis consumers possessed no greater risk than non-users to experience “serious adverse events.” Specifically, researchers identified no significant adverse changes in consumers’ cognitive skills, pulmonary function, or blood work following one-year of daily cannabis consumption. Medical cannabis consumers did report elevated risk of experiencing “non-serious adverse events” (e.g., cough, dizziness, paranoia) compared to controls; however, authors classified these to be “mild to moderate.”

Pain patients who used cannabis reported a reduced sense of pain compared to controls, as well as reduced anxiety, depression, and fatigue.

“Quality-controlled herbal cannabis, when used by cannabis-experienced patients as part of a monitored treatment program over one year, appears to have a reasonable safety profile,” authors concluded.

The study is one of the first to ever assess the long-term safety and efficacy of medicinal cannabis. A prior health review of patients receiving medical cannabis monthly from the US federal government as part of the Compassionate Investigational New Drug program similarly reported that cannabis possesses therapeutic efficacy and an acceptable side-effect profile.

- See more at: http://blog.norml.org/2015/09/21/study-daily-cannabis-use-for-chronic-pain-is-safe-effective/#sthash.DqnS90PL.dpuf

Chronic pain patients who use herbal cannabis daily for one-year report reduced discomfort and increased quality of life compared to controls, and do not experience an increased risk of serious side effects, according to clinical data published online ahead of print in the Journal of Pain.

Researchers at McGill University in Montreal assessed the long-term health of 216 medicinal cannabis users with chronic non-cancer pain who consumed a daily standardized dose (12.5 percent THC) of herbal cannabis compared to 215 controls (chronic pain suffers who did not use cannabis). Subjects in study were approved by Health Canada to legally use medicinal cannabis and consumed, on average, 2.5 grams of herb per day, typically via inhalation or vaporization.

Investigators reported that daily cannabis consumers possessed no greater risk than non-users to experience “serious adverse events.” Specifically, researchers identified no significant adverse changes in consumers’ cognitive skills, pulmonary function, or blood work following one-year of daily cannabis consumption. Medical cannabis consumers did report elevated risk of experiencing “non-serious adverse events” (e.g., cough, dizziness, paranoia) compared to controls; however, authors classified these to be “mild to moderate.”

Pain patients who used cannabis reported a reduced sense of pain compared to controls, as well as reduced anxiety, depression, and fatigue.

“Quality-controlled herbal cannabis, when used by cannabis-experienced patients as part of a monitored treatment program over one year, appears to have a reasonable safety profile,” authors concluded.

The study is one of the first to ever assess the long-term safety and efficacy of medicinal cannabis. A prior health review of patients receiving medical cannabis monthly from the US federal government as part of the Compassionate Investigational New Drug program similarly reported that cannabis possesses therapeutic efficacy and an acceptable side-effect profile.

- See more at: http://blog.norml.org/2015/09/21/study-daily-cannabis-use-for-chronic-pain-is-safe-effective/#sthash.DqnS90PL.dpuf
  1. Marijuana Relieves Chronic Pain, Research Shows
  • You are here:  
  • Home